Brighter appoints Erik Lissner as interim CEO
Brighter AB (Publ) announced today that its Board of Directors appoints Erik Lissner as interim CEO of Brighter effective immediately. Current interim CEO, Christer Trägårdh, will take the position as Chairman of the Board. The company has signed a six-month contract with Lissner and both parties are open to discuss a permanent solution after this period.
Erik Lissner is a strong leader and brings extensive CEO and executive level experience from large and small technology-driven publicly traded companies. He has worked most of his career within the MedTech sector, where he has been responsible for managing both start up’s and up to USD 75 million businesses with a focus on international B2B sales of security and medical device capital equipment, consumables and services on a global basis, both on a direct and indirect basis.
Most recently, Erik was the Director and Executive Advisor at Oxygy. Prior to that, he was the CEO of Papilly (Publ) and CEO of Biosensor Applications (Publ). Additionally, Erik has vast experience from various management positions within Johnson & Johnson Medical Devices. Erik holds an Executive MBA from Stockholm School of Economics and a BCS from Stockholm University.
“With the recruitment of Erik, Brighter will have an Interim CEO with broad experience within the MedTech sector and a leader who has successfully driven change and improved the performance of various businesses throughout his career. I am confident that Erik is the right person to bring Brighter into the company’s next chapter and that together with the Brighter team, he will continue to run the company towards new upcoming milestones. I look forward to remain in the company and contribute to the progress in my new role as Chairman of the Board, says Christer Trägårdh, previous interim CEO and new Chairman of the Board of Brighter AB.
For more information, please contact:
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG. https://brighter.se/
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 20:50 CET on July 20, 2021